These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 29807464)

  • 1. Opportunities and Challenges of Multinational Pharmaceutical Enterprises in Transforming Pharmaceutical Market in China.
    Hu L; Yu Z; Yuan Q; Hu Y; Ung COL
    Ther Innov Regul Sci; 2019 Mar; 53(2):207-214. PubMed ID: 29807464
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug policy in China: pharmaceutical distribution in rural areas.
    Dong H; Bogg L; Rehnberg C; Diwan V
    Soc Sci Med; 1999 Mar; 48(6):777-86. PubMed ID: 10190640
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Does the leading pharmaceutical reform in China really solve the issue of overly expensive healthcare services? Evidence from an empirical study.
    He Y; Dou G; Huang Q; Zhang X; Ye Y; Qian M; Ying X
    PLoS One; 2018; 13(1):e0190320. PubMed ID: 29338038
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Future European health care: cost containment, health care reform and scientific progress in drug research.
    Emilien G
    Int J Health Plann Manage; 1997; 12(2):81-101. PubMed ID: 10173136
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmaceutical supply chain in China: current issues and implications for health system reform.
    Yu X; Li C; Shi Y; Yu M
    Health Policy; 2010 Sep; 97(1):8-15. PubMed ID: 20307912
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [An analysis of the pharmaceuticals market in Vietnam].
    Simonet D
    Sante; 2001; 11(3):155-60. PubMed ID: 11641078
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The High Cost of Prescription Drugs in the United States: Origins and Prospects for Reform.
    Kesselheim AS; Avorn J; Sarpatwari A
    JAMA; 2016 Aug 23-30; 316(8):858-71. PubMed ID: 27552619
    [TBL] [Abstract][Full Text] [Related]  

  • 8. International experiences of promoting generics use and its implications to China.
    Sun J
    J Evid Based Med; 2013 May; 6(2):74-80. PubMed ID: 23829799
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of the effectiveness of comprehensive drug price reform: a case study from Shihezi city in Western China.
    Lin T; Wu Z; Liu M; Wu X; Zhang X
    Int J Equity Health; 2020 Aug; 19(1):133. PubMed ID: 32762691
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmaceutical pricing and reimbursement in China: When the whole is less than the sum of its parts.
    Hu J; Mossialos E
    Health Policy; 2016 May; 120(5):519-34. PubMed ID: 27080345
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmaceutical policy in China.
    Sun Q; Santoro MA; Meng Q; Liu C; Eggleston K
    Health Aff (Millwood); 2008; 27(4):1042-50. PubMed ID: 18607039
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Privatization of the medical market in socialist China: a historical approach.
    Liu G; Liu X; Meng Q
    Health Policy; 1994 Feb; 27(2):157-74. PubMed ID: 10133921
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Chinese pharmaceutical market at the crossroads: pro-competition solutions to improve access, quality and affordability.
    Wang YR
    Appl Health Econ Health Policy; 2005; 4(3):147-51. PubMed ID: 16309331
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Issues in drug pricing, reimbursement, and access in China with references to other Asia-Pacific region.
    Chen Y; Schweitzer SO
    Value Health; 2008 Mar; 11 Suppl 1():S124-9. PubMed ID: 18387056
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Healthcare reform in the United States and China: pharmaceutical market implications.
    Daemmrich A; Mohanty A
    J Pharm Policy Pract; 2014; 7(1):9. PubMed ID: 25097759
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug policy in China. Transformations, current status and future prospects.
    Liu X; Li S
    Pharmacoeconomics; 1997 Jul; 12(1):1-9. PubMed ID: 10169383
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Generic drug prices and policy in Australia: room for improvement? a comparative analysis with England.
    Mansfield SJ
    Aust Health Rev; 2014 Feb; 38(1):6-15. PubMed ID: 24480618
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impacts of regulated competition on pricing in Chinese pharmaceutical market under urban employee basic medical insurance.
    Zhao M; Wu J
    Expert Rev Pharmacoecon Outcomes Res; 2017 Jun; 17(3):311-320. PubMed ID: 27762144
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmaceutical cost-containment policy: experiences in Shanghai, China.
    Hu S; Chen W; Cheng X; Chen K; Zhou H; Wang L
    Health Policy Plan; 2001 Dec; 16 Suppl 2():4-9. PubMed ID: 11772985
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects on the medical revenue of comprehensive pricing reform in Chinese urban public hospitals after removing drug markups: case of Nanjing.
    Tang W; Xie J; Lu Y; Liu Q; Malone D; Ma A
    J Med Econ; 2018 Apr; 21(4):326-339. PubMed ID: 29139303
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.